| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0ff08a07cb599dbcb0627e242d13a49 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96486
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-705 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
| filingDate |
2006-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9129b769533fac30ef04a7bbb283804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a0c36030a8144fd84219384abe0c799 |
| publicationDate |
2011-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NZ-556561-A |
| titleOfInvention |
Adam-9 modulators |
| abstract |
Provided is a purified immunoglobulin produced by hybridoma ATCC No. PTA# 5174, or an antigen-binding fragment thereof that specifically binds to KID24, specifically binds to the same epitope on KID24 as antibody mu-anti-KID24 specifically binds, and has at least one of the following characteristics: a. the ability to bind to KID24 on a cancer cell; b. the ability to bind to a portion of KID24 that is exposed on the surface of a living cancer cell in vitro or in vivo; c. the ability to deliver a therapeutic agent or detectable marker to a cancer cell expressing KID24; and d. the ability to deliver a therapeutic agent or detectable marker into a cancer cell expressing KID24. The antibody is useful in the treatment of various cancers. |
| priorityDate |
2005-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |